Home / Health / Madrigal Pharma Strikes $4.4B Deal for Liver Disease Drugs
Madrigal Pharma Strikes $4.4B Deal for Liver Disease Drugs
11 Feb
Summary
- Madrigal Pharmaceuticals secured global rights to six preclinical siRNA programs.
- The deal with Suzhou Ribo Life Science could reach up to $4.4 billion.
- The therapies aim to treat metabolic dysfunction-associated steatohepatitis (MASH).
Madrigal Pharmaceuticals announced on February 11, 2026, that it has secured an exclusive global license for six preclinical small interfering RNA (siRNA) programs. The agreement was made with Suzhou Ribo Life Science and its subsidiary Ribocure, both based in China.
These siRNA programs are being developed to treat metabolic dysfunction-associated steatohepatitis (MASH), a severe liver condition that can lead to cirrhosis, liver failure, and cancer. Madrigal will have exclusive rights to develop, manufacture, and commercialize these compounds worldwide.
Suzhou Ribo Life Science will receive an initial payment of $60 million. The total value of the agreement could potentially reach $4.4 billion, contingent upon the successful achievement of specific development, regulatory, and commercial milestones. Additionally, Suzhou Ribo will benefit from future net sales through royalty payments.
